← All organizations
Highest phase reached
Phase 3
First clinical trial
Aug 1, 2008First marketed drug
Mar 6, 2018First NDA
Mar 6, 2018Last known activity
Dec 31, 2025
Timeline
2000s
- Jul 1, 2007
TaiMed Biologics Inc.— Founded
2010s
- Mar 6, 2018
ibalizumab-uiyk— Marketing Organization
- Mar 6, 2018
ibalizumab-uiyk— NDA Organization
Drugs by trial phase (2 distinct, 9 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Indications
Approved for
Studied for
Marketed drugs (1)
Recent trials (14)
- NCT07215468Lead sponsorPhase 2Dec 31, 2025
- NCT05275998Lead sponsorPhase 1/Phase 2Jul 5, 2022
- NCT04027387Study directorPhase 1Nov 30, 2019
- NCT04027387Lead sponsorPhase 1Nov 30, 2019
- NCT03913195Lead sponsorPhase 3May 30, 2019
- NCT03913195Study chairPhase 3May 30, 2019
- NCT02707861Lead sponsorPhase 3Mar 1, 2016
- NCT02707861Overall official - principal investigatorPhase 3Mar 1, 2016
- NCT02475629Lead sponsorPhase 3Aug 1, 2015
- NCT01292174Study directorPhase 1Feb 1, 2011
- NCT01292174Lead sponsorPhase 1Feb 1, 2011
- NCT01056393CollaboratorPhase 2Nov 1, 2009
- NCT00784147Study directorPhase 2Aug 1, 2008
- NCT00784147Lead sponsorPhase 2Aug 1, 2008
Details
- Founded
- Taipei, TW Jul 1, 2007
- First NDA
- Mar 6, 2018
- Last known activity
- Dec 31, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy